Repligen (NASDAQ:RGEN) Upgraded to Hold at StockNews.com

Repligen (NASDAQ:RGEN) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Friday.

Other equities research analysts also recently issued research reports about the stock. Evercore ISI assumed coverage on shares of Repligen in a research report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 price objective for the company. Royal Bank of Canada upped their target price on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a report on Friday, February 21st. JPMorgan Chase & Co. increased their price target on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. TD Cowen started coverage on Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price objective for the company. Finally, Canaccord Genuity Group increased their target price on Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. Seven analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $178.64.

Repligen Stock Down 8.0 %

Shares of Repligen stock opened at $111.94 on Friday. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The business has a 50-day moving average price of $150.03 and a 200 day moving average price of $147.58. Repligen has a fifty-two week low of $106.78 and a fifty-two week high of $182.52. The firm has a market cap of $6.29 billion, a P/E ratio of -219.49, a P/E/G ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. On average, sell-side analysts forecast that Repligen will post 1.72 earnings per share for the current fiscal year.

Insider Transactions at Repligen

In other news, Director Margaret Pax acquired 250 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were bought at an average price of $150.69 per share, with a total value of $37,672.50. Following the purchase, the director now owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Polar Asset Management Partners Inc. grew its stake in shares of Repligen by 76.9% in the 4th quarter. Polar Asset Management Partners Inc. now owns 6,900 shares of the biotechnology company’s stock worth $993,000 after purchasing an additional 3,000 shares during the last quarter. GTS Securities LLC bought a new stake in Repligen during the fourth quarter worth approximately $264,000. Gordian Capital Singapore Pte Ltd acquired a new position in Repligen in the fourth quarter worth approximately $259,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Repligen by 12.8% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 235,343 shares of the biotechnology company’s stock worth $33,875,000 after buying an additional 26,733 shares during the last quarter. Finally, Two Sigma Advisers LP increased its holdings in shares of Repligen by 6.7% in the fourth quarter. Two Sigma Advisers LP now owns 134,800 shares of the biotechnology company’s stock valued at $19,403,000 after buying an additional 8,500 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.